Myriad Genetics, Inc (NASDAQ: MYGN) is -78.26% lower on its value in year-to-date trading and has touched a low of $3.81 and a high of $29.30 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The MYGN stock was last observed hovering at around $5.12 in the last trading session, with the day’s loss setting it -2.88%.
Currently trading at $2.24M, the stock is 7.61% and -2.45% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.05 million and changing 1046416% at the moment leaves the stock -60.40% off its SMA200. MYGN registered -61.12% loss for a year compared to 6-month loss of -60.10%. The firm has a 50-day simple moving average (SMA 50) of $5.464 and a 200-day simple moving average (SMA200) of $13.4608.
The stock witnessed a 28.43% gain in the last 1 month and extending the period to 3 months gives it a -42.13%, and is 5.13% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 4.71% over the week and 6.30% over the month.
Myriad Genetics, Inc (MYGN) has around 2700 employees, a market worth around $491.31M and $831.30M in sales. Fwd P/E is 34.77. Profit margin for the company is -12.20%. Distance from 52-week low is 39.83% and -81.81% from its 52-week high. The company has generated returns on investments over the last 12 months (-11.91%).
with sales reaching $202.3M over the same period.The EPS is expected to shrink by -106.08% this year, but quarterly earnings will post -3.05% year-over-year. Quarterly sales are estimated to shrink -4.35% in year-over-year returns.
326.0 institutions hold shares in Myriad Genetics, Inc (MYGN), with institutional investors hold 107.28% of the company’s shares. The shares outstanding are 92.20M, and float is at 87.40M with Short Float at 9.59%. Institutions hold 104.32% of the Float.
The top institutional shareholder in the company is BLACKROCK INC. with over 15.15 million shares valued at $370.59 million. The investor’s holdings represent 16.7227 of the MYGN Shares outstanding. As of 2024-06-30, the second largest holder is VANGUARD GROUP INC with 10.06 million shares valued at $246.18 million to account for 11.1089 of the shares outstanding. The other top investors are WELLINGTON MANAGEMENT GROUP LLP which holds 8.26 million shares representing 9.1197 and valued at over $202.1 million, while CAMBER CAPITAL MANAGEMENT LP holds 6.0706 of the shares totaling 5.5 million with a market value of $134.53 million.
Myriad Genetics, Inc (MYGN) Insider Activity
The most recent transaction is an insider sale by DIAZ PAUL J, the company’s President and CEO. SEC filings show that DIAZ PAUL J sold 15,000 shares of the company’s common stock on Oct 11 ’24 at a price of $22.93 per share for a total of $0.34 million. Following the sale, the insider now owns 0.96 million shares.
